Polygenic disease associations in thymomatous myasthenia gravis

Archives of Neurology

Volumn 64, Issue 12, 2007, Pages 1729-1733

  Amdahl, Christian ^a   Alseth, Espen H ^a   Gilhus, Nils E ^a,b   Nakkestad, Hanne L ^a   Skeie, Geir O ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CONNECTIN; FC RECEPTOR IIA; INTERLEUKIN 10; LYMPHOTOXIN; NICOTINIC RECEPTOR; RECEPTOR ANTIBODY; RYANODINE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; MYASTHENIA GRAVIS; PRIORITY JOURNAL; THYMOMA;

ALLELES; ANTIGENS, CD; AUTOANTIBODIES; DNA; GENETIC MARKERS; GENOTYPE; HUMANS; INTERLEUKIN-10; LYMPHOTOXIN-ALPHA; MUSCLE PROTEINS; MYASTHENIA GRAVIS; PROTEIN KINASES; RECEPTORS, IGG; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; THYMOMA; THYMUS NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; VARIATION (GENETICS);

EID: 37149036028     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.12.1729     Document Type: Article

References (35)

1. Vincent A, Drachman DB. Myasthenia gravis. Adv Neurol. 2002;88:159-188.
2. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797- 1810.
3. Hughes BW, Moro De Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol. 2004;24(1):21-30.
4. Somnier FE. Myasthenia gravis. Dan Med Bull. 1996;43(1):1-10.
5. Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001;58(6):885-890.
6. Skeie GO, Aarli JA, Gilhus NE. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand Suppl. 2006;183:19-23.
7. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol. 2000;57(11):1596-1600.
8. Vandiedonck C, Beaurain G, Giraud M, et al. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci U S A. 2004;101(43):15464-15469.
9. Skeie GO, Pandey JP, Aarli JA, Gilhus NE. TNFA and TNFB polymorphisms in myasthenia gravis. Arch Neurol. 1999;56(4):457-461.
10. Raknes G, Skeie GO, Gilhus NE, Aadland S, Vedeler C. FcgammaRIIA and Fc-gammaRIIIB polymorphisms in myasthenia gravis. J Neuroimmunol. 1998;81(1-2):173-176.
11. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103(3):579-601.
12. Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics. 1990;31(5-6):285-290.
13. Spurkland A, Gilhus NE, Rønningen KS, Aarli JA, Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens. 1991;37(2):90-93.
14. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol. 1993;47(2):115-122.
15. Gilhus NE, Pandey JP, Gaarder PI, Aarli JA. Immunoglobulin allotypes in myasthenia gravis patients with a thymoma. J Autoimmun. 1990;3(3):299-305.
16. Skeie GO, Pandey JP, Aarli JA, Gilhus NE. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes. Autoimmunity. 1997;26(2):111-116.
17. Giraud M, Beaurain G, Yamamoto AM, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 2001;57(9):1555-1560.
18. Lefvert AK, Bergström K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry. 1978;41(5):394-403.
19. Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology. 1993;43(8):1581-1585.
20. Botto M, Theodoridis E, Thompson EM, et al. Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol. 1996;104(2):264-268.
21. Zelano G, Lino MM, Evoli A, et al. Tumour necrosis factor beta gene polymorphisms in myasthenia gravis. Eur J Immunogenet. 1998;25(6):403-408.
22. Zelano G, Settesoldi D, Lino MM, Batocchi A, Evoli A, Tonali PA. Thymic disorders and myasthenia gravis: genetic aspects. Ann Med. 1999;31(suppl 2):46-51.
23. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94(7):3195-3199.
24. Messer G, Spengler U, Jung MD, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991;173(1):209-219.
25. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24(1):1-8.
26. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991;147(4):1338-1343.
27. Gomez CM, Richman DP. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol. 1985;135(1):234-241.
28. Rødgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67(1):82-88.
29. Romi F, Skeie GO, Vedeler C, Aarli JA, Zorzato F, Gilhus NE. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis: a study of IgG subclasses and clinical correlations. J Neuroimmunol. 2000;111(1-2):169-176.
30. Kornstein MJ, Asher O, Fuchs S. Acetylcholine receptor alpha-subunit and myogenin mRNAs in thymus and thymomas. Am J Pathol. 1995;146(6):1320- 1324.
31. Mygland A, Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol. 1995;62(1):79-83.
32. Romi F, Bø L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 2002;128(1-2):82-89.
33. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000;96(12):3872-3879.
34. Luther C, Poeschel S, Varga M, Melms A, Tolosa E. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol. 2005;164(1-2):124-128.
35. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol. 1990;28(3):312-319.